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Wntwhich is the best-characterized the multiple Wnt signaling branches. The past 10 years has
seen a rapid expansion in our understanding of the complexity of this pathway, as many
new components of Wnt signaling have been identified and linked to signaling regulation, stem
cell functions, and adult tissue homeostasis. Additionally, a substantial body of evidence links
Wnt signaling to tumorigenesis of cancer types and implicates it in the development of cancer
drug resistance. Thus, a better understanding of the mechanisms by which dysregulation of
Wnt signaling precedes the development and progression of human cancer may hasten the
development of pathway inhibitors to augment current therapy. This review summarizes and
synthesizes our current knowledge of the canonical Wnt pathway in development and disease.
We begin with an overview of the components of the canonical Wnt signaling pathway and
delve into the role this pathway has been shown to play in stemness, tumorigenesis, and can-
cer drug resistance. Ultimately, we hope to present an organized collection of evidence impli-
cating Wnt signaling in tumorigenesis and chemoresistance to facilitate the pursuit of Wnt
pathway modulators that may improve outcomes of cancers in which Wnt signaling contributes
to aggressive disease and/or treatment resistance.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Fig. 1 The initial upstream signaling components of the
Wnt signaling pathways include Frizzled receptor (Fz),
co-receptor, and Dishevelled (Dsh). (1) Extracellular binding
of Wnt to the cysteine-rich domain (CRD) of Fz leads to
membrane localization of a co-receptor which may directly
bind the Wnt ligand, and (2) recruitment of the phosphoprotein
Dsh to the intracellular membrane leaflet. Dsh activates spe-
cific downstream effectors leading to induction of a specific
arm of Wnt signaling. The specificity of activation is deter-Introduction
Wnt signaling regulates a group of evolutionarily conserved
pathways which play a central role in a diverse set of
cellular activities including cell proliferation, calcium ho-
meostasis, and cell polarity.1e5 Discovery of these pathways
began in 1982 when, in their study of virally-induced C3H
murine breast tumors, Nusse and Varmus identified a 25 kb
region named Int-1, so called for being the preferential
integration site of the mouse mammary tumor virus
(MMTV).6 Following sequencing of Wnt1, the Drosophila
gene wingless (wg) was shown to be a homolog of Wnt1.7,8
Originally identified in a classic genetic screen by Nu¨sslein-
Volhard & Wieschaus, wg was known to control segment
polarity in larval development of Drosophila.9 Taken
together, these initial results began to hint at the scope and
diversity of Wnt signaling. Evolutionary conservation of Wnt
signaling was established following demonstration by
McMahon and Moon that injection of mouse Wnt1 mRNA in
Xenopus embryos at the 4-cell stage led to duplication of
the body axis e a positive indicator of Wnt signaling.
Although the role of Wnt signaling in human disease, spe-
cifically cancer, was arguably hinted at by Nusse and Var-
mus when they discovered Int-1 as a locus for oncogenic
proviral integration, an undisputed connection was estab-
lished only when adenomatous polyposis coli (APC ), the
gene underlying the hereditary cancer syndrome familial
adenomatous polyposis (FAP), was identified and subse-
quently found to interact with b-catenin.10e12
Historically, Wnt signaling has been classified into two
large categories: the canonical Wnt (or b-catenin-depen-
dent) and non-canonical Wnt (or b-catenin-independent)
pathways. The canonical and non-canonical pathways are
intersecting signaling networks (Fig. 1) that coordinately
regulate complex processes, such as embryonic develop-
ment, stem cell maintenance, tissue homeostasis, and
wound healing.1 The better-understood canonical Wnt/b-
catenin pathway regulates cell fate, proliferation, and
survival, while non-canonical Wnt pathways are more often
associated with differentiation, cell polarity, andmigration. Non-canonical Wnt signaling can be initiated by
Wnt interaction with Frizzled receptors (Fzs), or RYK and
ROR receptor tyrosine kinases and has been shown to
regulate small GTPases (such as RhoA, Rac, and
Cdc42).1e3,5 Non-canonical Wnt signaling can also activate
calcium flux and kinase cascades, including those of protein
kinase C (PKC), calcium/calmodulin-dependent protein ki-
nase II (CaMKII), and JUN N-terminal kinase (JNK), leading
to the activation of gene expression mediated by themined by which domains interact with Fz.
Wnt signaling in stem cell biology and tumorigenesis 13transcription factors activating protein 1 (AP1) and nuclear
factor of activated T cells (NFAT).1e3 While it is apparent
that non-canonical Wnt pathways play important roles in
regulating many critical cellular processes, and Wnt
signaling at large exhibits extensive cross-talk with other
evolutionarily conserved signaling pathways, this review
will focus on the canonical Wnt pathway, highlighting its
major components, the roles it plays in regulating stem cell
self-renewal and fate, and its implication in the develop-
ment of human diseases, particularly cancer.1e3Fig. 2 Inactivation and proteosomal degradation of b-cat-
enin is inhibited by activation of canonical Wnt signaling. (A)
In the absence of canonical Wnt signaling, phosphorylation of
b-catenin at key residues by GSK-3 and CK-1 occurs constitu-
tively and is facilitated by the scaffolding proteins APC and
Axin. Phosphorylation at N-terminal serine and threonine res-
idues creates a binding site for the ubiquitin ligase SCFb-TrCP
and targets b-catenin for proteosomal degradation. (B) Acti-
vation of canonical Wnt signaling by binding of a canonical Wnt
ligand to Fz and LRP-5/6 co-receptor recruits Axin to the inner
membrane leaflet via interactions with Dsh and LRP-5/6,
thereby disrupting the b-catenin destruction complex. Stable
b-catenin is able to accumulate in the cytosolic and nuclear
compartments. In the nucleus, b-catenin displaces the co-
repressor protein Groucho from TCF/LEF transcription factors
and, with the help of co-activators such as CBP or p300 (not
pictured) initiates transcription of target genes.Essential components and flow of the Wnt
signaling pathway
Wnt signaling begins with secretion of one of the 19 Wnt
ligands and is initiated by Wnt ligands binding extracellu-
larly to a complex consisting of their cognate receptor,
Frizzled (Fz), and a co-receptor, such as LDL-related pro-
tein receptor 5/6 (LRP-5/6) in the canonical pathway
(Fig. 1). Activation of Fz leads to recruitment of the cyto-
plasmic phosphoprotein Dishevelled (Dsh). Induction of one
of multiple possible signaling cascades follows e either the
canonical pathway (Fig. 2) or one of several non-canonical
pathways. The two best-characterized non-canonical
pathways are the planar cell polarity pathway, which reg-
ulates the polarity of epithelial cells by modifying the actin
cytoskeleton (Fig. 3), and the Wnt/Ca2þ pathway, which
regulates the release of intracellular Ca2þ stores
(Fig. 4).13e15 Several other non-canonical pathways have
been proposed with significant overlap, and are reviewed
more thoroughly elsewhere.1e3 In this review, we focus on
the canonical Wnt/b-catenin pathway, which is better-
characterized and appears to play a more prominent role
in human disease.
Wnt ligands are an evolutionarily-conserved but
poorly-characterized family of pleiotrophic,
cysteine-rich, and lipid-modified glycoproteins
Wnt proteins are a family of 19 highly-preserved w40 kDa
secreted glycoproteins.16 They contain an N-terminal
signaling sequence and a conserved set of 22e24 cysteine
(Cys) residues.17,18 Sequencing data suggests the possibility
of intramolecular disulfide bonds, likely promoting confor-
mational stability. Additional post-translational modifica-
tions include N-glycosylation and lipidation (O-acylation) of
conserved Cys residues.19,20 The insolubility and hydropho-
bicity of Wnt ligands, due to the addition of a palmitoyl
adduct to conserved Cys residues, has precluded their com-
plete biochemical characterization by confounding the
ability to isolate Wnt ligands in their active form.20 Further,
there is poor overlap between the primary sequences of Wnt
ligands and those of commonly known protein folds and mo-
tifs.21 Beyond complicating the ability to fully characterize
Wnt ligands, the role of lipid modification has yet to be fully
identified. Although loss of the palmitatemoiety bymutation
or enzymatic removal is associated with a loss of Wnt
signaling activity, a precise description of its role remains
elusive.20,22 More recent experimentation demonstrates that
it may interact directly with a binding site on Fz.21Regulation of Wnt ligand secretion hinges on lipid
modification by the O-acyltransferase Porcupine
As is true for many secreted signaling molecules, post-
translational lipid modifications play a critical role in the
regulation of Wnt secretion. Loss of lipid modifications,
including palmitoyl acylation, in Drosophila leads to
Fig. 3 The planar cell polarity (PCP) pathway regulates
epithelial cell and tissue polarity by regulating the actin
cytoskeleton. Following non-canonical Wnt ligand binding to
Fz and co-localization of a co-receptor, Dsh is activated and
localized to the inner membrane leaflet. PDZ and DEP domains
simultaneously activate small GTPases Rho and Rac through
parallel pathways, as well as the actin-binding protein Profilin.
Activation of Rho and Profilin occur through a Dishevelled
associated activator of morphogenesis 1 (Daam1)-dependent
pathway; Rac activation is Daam1-independent. Activation of
Rho-associated kinase (ROCK) and myosin occur downstream of
Rho activation, leading to modification and rearrangement of
the actin cytoskeleton. Rac GTPase activates JNK, whose
downstream effects leading to cytoskeletal modification
remain poorly characterized. This cytoskeletal modification
regulates both the apical-basal polarity of cells and the po-
larity of cells within an epithelial layer.
Fig. 4 Activation of the Wnt/Ca2D pathway triggers the
release of intracellular calcium stores. In the Wnt/Ca2þ
pathway, binding of Wnt ligand to Fz activates G-proteins,
which in turn activate Dsh. Activated Dsh binds phosphodies-
terase (PDE), which inhibits Protein Kinase G (PKG) and causes
an increase in intracellular calcium, as well as the enzyme
phospholipase C (PLC). Activated PLC produces inositol
triphosphate (IP3) and 1,2-diacylglycerol (DAG) from the
membrane-bound phospholipid phosphatidyl inositol 4,5-
bisphosphate. IP3 triggers release of intracellular Ca
2þ from
stores in the endoplasmic reticulum (ER), which activates a
number of downstream targets, including CamKII, calcineurin,
and protein kinase C (PKC). Activation of PKC by Ca2þ requires
DAG, and leads to phosphorylation and activation of cell divi-
sion control protein 42 (Cdc42), a GTPase. Activation of cal-
cineurin by Ca2þ and calmodulin (not pictured),
dephosphorylates and activates the nuclear factor associated
with T cells (NFAT) family of transcription factors, thereby
facilitating transcription of their target genes and linking
intracellular Ca2þ signaling to gene expression. Target genes of
the NFAT family include genes critical for the immune
response, but have also been shown to influence ventral cell
fates in vertebrate embryos. Finally, CamKII activation has a
downstream effect that includes antagonizing b-catenin/TCF
regulated transcription.
14 M.K. Mohammed et al.absence of Wg on extracellular staining, demonstrating
that lipid modifications are required for secretion of
Wg.23 Palmitoyl acyl groups are normally present on both
C93 and S239 residues in Wg. Tang et al demonstrated
that while single mutants at either C93 or S239 can be
secreted, mutation of both residues completely inhibits
secretion. Further evaluation revealed that both
acyl groups are required for interaction with Wntless
(Wls), a cargo receptor participating in Wg secretion.
However, in the same study, the authors suggest that
modification at S239 plays a more important role in the
regulation of Wnt signaling. Unlike Wg C93 mutants, S239
Wnt signaling in stem cell biology and tumorigenesis 15mutants demonstrated reduced binding with its cognate
receptor Drosophila Frizzled 2 (dFz2), suggesting an
indispensable role for the S239 residue in the formation of
a receptor-ligand complex.23 By comparison, murine
Wnt3a demonstrated loss of signaling activity with no
inhibition of secretion following mutation of C77.20 Loss
of acylation at S209 of murine Wnt3a results in failure of
ligand secretion and sequestration in the endoplasmic
reticulum.24
The O-acyltransferase Porcupine, responsible for O-
acylation of Wnt, was initially discovered in Drosophila.
Porcupine is a segment polarity gene encoding a trans-
membrane protein localized to the ER membrane and
playing a role in Wg processing.25 The purported O-ace-
tyltransferase activity of Porcupine was supported by
sequence homology with a family of known membrane-
bound O-acyltransferases and confirmed experimen-
tally.26,27 Murine, Xenopus, and human homologues were
subsequently identified and found to encode multi-pass
transmembrane ER proteins with similar structure and
function as Porcupine.28,29 Evidence supporting a role for
Wnt regulation in vertebrate species by Porcupine was
reported later, after lipid-modification of Wnt1 and Wnt3a
by porcupine was demonstrated in chick neural tube
cells.30
The purported role of lipid modification is to target Wnt
to secretory vesicles and create a high local concentration
of ligand following secretion. It has previously been hy-
pothesized that acylation may play a role in intracellular
trafficking of Wnt by targeting it to specific organelles or to
intracellular lipoprotein particles.24 Zhai et al demon-
strated that lipid-modification of Wg targets it to secretory
vesicles, which deliver the ligand to unique microdomains
at the cell surface for packaging prior to secretion.31 Inhi-
bition of O-acetyltransferase activity with 2-
bromopalmitate inhibited, in a concentration-dependent
manner, the incorporation of Wg into lipid rafts. Similar
results were obtained using cell lysates of Porcupine-
negative mice with constitutive expression of Wg relative to
control animals (6.69% membrane association of DWnt1 vs
80.76% in wildtype animals).31
Lipid modifications of ligands such as hedgehog and
epidermal growth factor have been shown to enhance
their association with the plasma membrane, thus allow-
ing for achievement of a local concentration high enough
for biological activity.32,33 In the case of Wnt, loss of
Porcupine-mediated lipid modification has been shown to
reduce the range of activity for Wnt1/3a in the chick
neural tube and cause intracellular retention of Wg in
Drosophila models.30 Overexpression of Wls in Drosophila
embryos has been shown to overcome the absence of
Porcupine.20,34 Of note, the more newly characterized
Drosophila WntD has not been shown to require lipid-
modification for secretion at high levels.35e37 Despite
these occasionally conflicting results, it remains clear that
post-translational modification plays an important role in
regulating intracellular trafficking and secretion of Wnt
ligands. Unlike lipid modification, current evidence does
not support a critical role for N-glycosylation in the
regulation of Wnt secretion. Loss of all N-glycosylations on
Wg has no demonstrated effect on secretion or
signaling.23Secretion of Wnt is modulated by the multi-pass
transmembrane protein Wntless
Secretion of Wnt proteins is mediated by the Wnt-binding
protein Wntless (Wls, also known as Evi, or GPR177), which
transports Wnt from the Golgi network to the cell surface
for release.38 Discovered in Drosophila during a screen for
suppressors of a gain-of-Wg-signaling phenotype in the
Drosophila eye, Wntless is a segment-polarity gene
encoding a functionally conserved Type II multipass trans-
membrane protein and is a transcriptional target of Wnt
signaling.38e40,41(p177),42 Wls is analogous to Dispatched, a
protein functioning to secrete Hedgehog (Hh) proteins.43
Homozygous loss of Wntless is associated with abnormal
patterning during fetal development, suggesting that it is
necessary for proper Wnt functioning38 Wls contains seven
transmembrane regions and is thought to act downstream
in the cascade from Porcupine.38 Wls is hypothesized to
function as a cargo receptor for Wnt, transporting it from
the trans-golgi to the plasma membrane. Wls itself is then
recycled back to the cis-golgi via retromer complex ma-
chinery, but separate from other retromer cargo through a
morphologically distinct retrieval pathway.44
Following secretion, Wnt is stabilized by
extracellular matrix proteins
Regulation of Wnt signaling continues after secretion, pri-
marily via interactions with extracellular proteins. Heparan
sulfate proteoglycans (HSPGs) in the extracellular matrix
(ECM) stabilize and maintain the activity of hydrophobic
Wnt ligands by preventing their aggregation in the aqueous
extracellular milieu. This likely occurs by direct bonding of
HSPGs to Wnt, as has been demonstrated previously with
glypican-1 and XWnt8. It remains to be seen if there exists
specificity in the interactions between HSPGs and Wnt
ligands.45,46
Wnt ligands bind to the Frizzled family of receptors
to initiate signaling
The Frizzled (Fz) family of receptors are the cognate re-
ceptors through which Wnt signaling primarily occurs. They
are classified as a novel family of transmembrane G-protein
coupled receptors (GPCRs) withw7 transmembrane regions
and an N-terminal sequence enriched with w10 Cys resi-
dues.47e49 There is plurality in which Fz specific Wnts may
bind to; a single Wnt can bind any one of multiple Frizzled
(Fz) proteins.47 Encoded by the Drosophila gene family,
frizzled Drosophila frizzled 2 (Dfz2) was the first member
of the family discovered to be capable of activating
downstream components of Wnt signaling.47 A vertebrate
homolog, Rat frizzled-1 (Rfz1) was discovered soon there-
after to also induce expression of Wnt-responsive genes.50
Additional family members and vertebrate homologues
have since been discovered. The International Union of
Pharmacology (IUPHAR) recognizes 10 mammalian isoforms
of the Fz receptor.51
Wnt ligands interact with Fz through its N-terminal
cysteine-rich domain (CRD) (Fig. 1). In early experiments,
transfection with this domain alone was enough to confer
16 M.K. Mohammed et al.Wg-binding in a Drosophila model.47,52 With the successful
production of Xenopus Wnt8 (XWnt8) in biologically active
form, quantitative biochemical experiments on Wnt
signaling are now possible, including those studying the
receptor-ligand interaction.52 In fact, the complex of
XWnt8 bound to the Fz CRD has been crystallized success-
fully and provided information on the structural basis for
recognition of Wnt by Fz. XWnt8 was shown to bind Fz-CRD
through two domains described as a ‘thumb’ and ‘index
finger’ extending from the ‘hand’ that is the remainder of
the Wnt protein. At the first site, a long tube of electron
density from the Fz-CRD engages with a palmitoleic acid
lipid group projecting from the S187 located at the ‘thumb’
of Wnt into said tube of the CRD. A set of hydrophobic
amino acids at the tip of the ‘index finger’ domain is in
contact with a depression on the side of Fz-CRD opposite
from the first binding site.21
In addition to Wnt, at least 3 additional families of li-
gands, soluble Fz-related proteins (sFRPs), Norrin, and R-
spondins, have been shown to directly bind Fz and stimu-
late downstream signaling (see below).53e57 Connective
tissue growth factor (CTGF) binds the CRD of Fz as well, but
inhibits downstream signaling, suggesting a possible role as
an endogenous competitive antagonist.58Wnt signal transduction occurs through ligand-
induced receptor dimerization and recruits the
phosphoprotein Dishevelled to the intracellular
membrane leaflet
The mechanism by which binding of Wnt and other ligands
activates Fz and initiates intracellular signal transduction
remains poorly characterized. Receptor dimerization and
oligomerization, which been demonstrated in other mem-
bers of the GPCR family both immediately after synthesis
and in a ligand-promoted manner, have been proposed as
possible mechanisms.59e61 Crystallization of CRDs from
both murine Fz8 and sFRP3 yielded homodimers with
observed overlap between the Wnt-binding domain and the
homodimer interface, suggesting that ligand-induced re-
ceptor dimerization may be a key step in signal trans-
duction.62 Formation of Xfz3 dimers has been demonstrated
independent of ligand-binding by Western blot and co-
immunoprecipitation when overexpressed in Xenopus em-
bryos. The truncated protein Xfz3DC has been shown to be
capable of forming homodimers and oligomers, suggesting
that only the N-terminal domain is required for dimer for-
mation. This finding is consistent with previous observations
that the N-terminal CRD is capable of homodimer forma-
tion. Of note, dimerization of Xfz3 was demonstrated to be
sufficient for activation of Wnt/b-catenin signaling inde-
pendent of ligand. Although Xfz7 was shown in the same
study to be unable to dimerize, dimerization of Xfz7 could
be observed following addition of a heterologous dimer-
ization domain.60 Taken together, these results suggest the
possibility of ligand-induced dimerization as a mechanism
by which the WnteFz interaction activates the intracellular
signaling cascade. However, as these experiments still offer
no direct evidence of ligand-induced dimerization, further
experimentation is necessary to validate this hypothesis. It
has been further proposed that, given the multiplepathways through which Fz may signal, dimerization may
confer transduction specificity.60
Once activated, Fz recruits the phosphoprotein Dishev-
elled (Dsh/Dvl) to the intracellular membrane leaflet. Dsh
acts as a signal transduction molecule, activating down-
stream effectors in response to Fz activation.63e65 Dsh is a
conserved protein originally identified as a gene important
for body/wing orientation in Drosophila; loss of Dsh resul-
ted in a phenotype characterized by misalignment of wing
and body hairs.66 Since then, three homologues (Dvl 1, 2, 3)
have been identified in humans and mice.63,66 Dvl contains
three conserved domains, an N-terminal DIX (80 aa), cen-
tral PDZ (w90 aa), and a C-terminal DEP (80 aa), each
involved in specific proteineprotein interactions and lead-
ing to activation of a specific arm of Wnt signaling (Fig. 1).67Canonical Wnt signaling stabilizes the dual-function
protein b-catenin
The canonical pathway of Wnt signaling regulates the
degradation of b-catenin, a protein with roles in stabilizing
cell adhesion and as a transcriptional activator of cell
proliferation pathways. Of the three Wnt signaling path-
ways, it is the best-characterized. The pathway can
perhaps be best understood by contrasting its configuration
in the ‘off’ state (Fig. 2A), without Wnt activation, to that
in the ‘on’ state, or once it has been activated by Wnt
binding to Fz (Fig. 2B).68
In the absence of Wnt signaling, b-catenin is
constitutively degraded
Under physiologic conditions, the canonical Wnt signaling
pathway spends most of its time in the ‘off’ configuration,
where Fz is inactive and a complex of proteins known as the
b-catenin destruction complex exists in the cytoplasm
(Fig. 2A). The complex includes the tumor suppressors Axin,
adenomatous polyposis coli (APC), the Ser/Thr kinases
glycogen synthase kinase 3 (GSK-3) and casein kinase 1
(CK1), and the F-box protein b-transducin repeat-
containing protein (b-TrCP).69,70 Protein phosphatase 2A
(PP2A) is also known to associate with the complex and may
fulfill a regulatory role.71e74 The specifics are reviewed in
detail elsewhere by Stamos and Weis.69 This review will
focus on the functional highlights of the complex and its
role in the signaling cascade.
b-Catenin is targeted for proteolysis in a two-step pro-
cess beginning with phosphorylation of an N-terminal
conserved Ser/Thr-rich sequence to create a b-TrCP binding
site for subsequent ubiquitination.75e78 The first step,
phosphorylation of Ser45 by CK1, is facilitated by a cluster
of acidic residues located seven amino acids downstream
from the phosphorylation site.79,80 Successive phosphory-
lation of T41, S37, and S33 by GSK-3 follows; phosphoryla-
tion of each residue primes the next phosphorylation step.
Together, the phosphorylated residues create a binding site
for b-TrCP. Mutations in the gene encoding b-catenin,
CTNNB1, which altered GSK-3b phosphorylation sites
created mutant copies of b-catenin with six times higher
activity than its wild-type counterpart.81 Binding of b-TrCP
triggers recruitment of the protein subunits Cul1/Cdc53 and
Skp1 to form the ubiquitin ligase SCFb-TrCP.82 The ensuing
Wnt signaling in stem cell biology and tumorigenesis 17ubiquitination of b-catenin targets it for proteasome-
mediated destruction.83,84
Axin and APC play crucial scaffolding roles in facilitating
destruction of b-catenin
Although not involved directly in enzymatic modification of
b-catenin, Axin and APC play crucial roles in facilitating
destruction of b-catenin. Axin is a large (w96 kDa) and
flexible protein containing binding sites for APC, CK1, GSK-
3, and b-catenin, as well as a purported binding site for
PP2A or another phosphatase.71,73(p61),85e89 While
Drosophila contains only one gene for Axin, vertebrate
genomes encode two mechanistically interchangeable var-
iants.90,91 Axin has been shown to enhance GSK-3-mediated
phosphorylation of b-catenin by a factor of approximately
20,000.92 This enhancement is attributed to a “scaffold
effect” created by Axin simultaneously binding b-catenin
and a kinase, thereby increasing the effective concentra-
tion of enzyme and substrate.87,93 The possibility of Axin
modulating kinase catalytic activity has been ruled out by
analysis of crystal structures, which show Axin binding to
regions of GSK-3 and CK1 far-removed from their respective
catalytic sites and demonstration of unchanged enzyme
kinetics following binding to Axin.92,94
APC is an even larger (w310 kDa) multi-domain protein
containing short peptide motifs which bind b-catenin and
Axin.95 b-Catenin binds at homologous repeats of 15e20
amino acids.96 Phosphorylation of these sites can be
mediated by GSK-3 or CK1 and has been demonstrated to
increase APC binding affinity for b-catenin by up to 1500-
fold. Axin binds APC at w16-amino acid conserved re-
peats named ‘SAMP repeats’, which are interspersed be-
tween b-catenin binding sites.85 Vertebrate APC
additionally contains N-terminal dimerization domains and
an armadillo repeat domain which interacts with cytoskel-
etal regulatory molecules and the B56 regulatory subunit of
PP2A.97e102
Although the role of APC in the destruction complex
remains unclear, the literature presents the following
working hypotheses69:
(1) APC may promote phosphorylation of b-catenin by
Axin-bound kinases. Although structural analysis
supports this hypothesis and suggests that APC is
capable of scaffolding the Axin-b-catenin interaction,
APC fragments containing b-catenin and Axin binding
sites did not demonstrate any enhancement of b-
catenin phosphorylation.103e105 Similarly, no decrease
in b-catenin phosphorylation occurs when APC
is mutated to produce a truncated copy lacking
SAMP repeats.106 However, the literature remains
conflicted. In a more recent experiment, a fragment
of APC including b-catenin and Axin-binding regions
was shown to directly phosphorylate b-catenin and
other substrates of GSK-3.107
(2) APC may facilitate cycling of the b-catenin
destruction complex. Based on studies demon-
strating that APC, when phosphorylated at 20-amino
acid repeat sites, competes with Axin to bind b-cat-
enin, Kimelman and Xu proposed a model where APC
is phosphorylated by CK1 and GSK-3 after they act on
b-catenin. Phosphorylated APC displaces Axin from b-catenin, thereby freeing Axin to bind a new b-catenin
molecule.93,108,109 Dephosphorylation by PP2A resets
the destruction complex.71,73,110 Caveats to this
model of APC function include lack of supporting data
from in vitro studies. Ha et al demonstrated that
protein phosphatase 1 (PP1), an enzyme with a cat-
alytic domain similar to PP2A, was unable to de-
phosphorylate b-catenin-bound phosphorylated APC
over a span of 3 hours e a period of time considerably
longer than the documented half-life of b-
catenin.109,111
(3) APC may promote b-catenin ubiquitination. Ubiq-
uitination of b-catenin requires the presence of APC
20-mer repeat 2 (20R2), a domain that does not bind
b-catenin.112e114 Inability of b-TrCP to co-precipitate
b-catenin in cell lines bearing copies of APC truncated
before 20R2 and restoration of co-precipitation by
transfecting the cells with wild-type APC suggests
that 20R2 and the associated conserved downstream
sequence stabilize the interaction between b-TrCP
and b-catenin.105
(4) APC may sequester b-catenin in the cytoplasmic
compartment. Sequestering b-catenin in the cyto-
plasm prior to proteasome-mediated destruction is
necessary to prevent inappropriate activation of
downstream signaling. Using fluorescence recovery
after photobleaching (FRAP) to observe inter-
compartmental movement of b-catenin,
Krieghoff et al demonstrated that APC and Axin
increased the concentration of cytoplasmic b-catenin
independently of the nuclear transport protein CRM-
1. However, neither elicited an effect on nuclear-
cytoplasmic shuttling, suggesting they simply pro-
mote cytosolic retention of b-catenin.115 Data from
multiple studies has been unable to pinpoint one b-
catenin-binding repeat of APC as being essential for
cytoplasmic retention.109,114 Ha et al proposed a
model in which APC contains both high-affinity and
low-affinity binding sites such that b-catenin can be
sequestered regardless of its cytoplasmic concentra-
tion.109 However, as Stamos and Weis explain, their
model does not yet explain how Axin is able to access
b-catenin and act as a scaffold to promote its
phosphorylation.69
(5) APC may facilitate localization of the destruction
complex. APC has been shown to localize in verte-
brate cells to the basolateral cortex or to cellecell
junctions through its interactions with the microtu-
bule and Axin cytoskeletons.103,116,117 Truncated APCs
have demonstrated more efficient transit between
the nucleus and cytoplasm likely due to fewer cyto-
skeletal interactions.118
Independent of its role in regulation of b-catenin sta-
bility, APC associates with the microtubule cytoskeleton as
shown by in vivo immunofluorescence. Association occurs
through the C-terminus of the full-length protein and has
been shown by in vitro polymerization and immunofluo-
rescence assays to promote assembly of microtubule ar-
rays.119 The complexity of APC’s role in Wnt signaling is due
in part to its multifunctionality.120 Although the data dis-
cussed above suggest several possible roles for APC, further
18 M.K. Mohammed et al.studies are needed for a complete understanding of its
function with respect to b-catenin destruction.
Activation of the canonical pathway leads to receptor
dimerization, co-receptor LRP-5/6 localization, and
recruitment of scaffolding proteins Dvl and Axin
Activation of the canonical pathway occurs with binding
of Wnt to the extracellularly-located CRD of Fz and to the
co-receptor (LRP-5/6) (Fig. 2A). LRP-5 and LRP-6 are type
I single-span transmembrane proteins discovered through
their homology to the LDL-receptor.121,122 Unlike the
other members of the LDL-receptor (LDL-R) family, they
contain four b-propeller/epidermal growth factor (PE)
and three LDL-R repeats in the extracellular domain as
well as Pro-rich motifs on the intracellular domain.121
Wnts have been shown to directly bind LRP-5/6 at PE
domains.123,124
Genetic studies comparing developmental abnormalities
associated with loss of LRP-5 and LRP-6 suggest they have
overlapping functions, but that loss of LRP-6 is associated
with more severe defects.125 Combined with studies
showing that overexpression of LRP-6 demonstrates stron-
ger activity than overexpression of LRP-5 in both Xenopus
and mammalian cells, it is possible that LRP-6 has a higher
affinity for Wnts, a stronger signaling efficacy, or
both.126e128
Once Wnt is bound and the trimeric complex of Fz and
LRP-5/6 is formed, downstream signaling is transduced
through the scaffold proteins Dsh/Dvl and Axin (Fig. 2B). Dvl
appears to engage the C-terminal KTxxxW motif of Fz
through multiple domains.129e131 Dvl then becomes hyper-
phosphorylated after associating with kinases, including
CK1- 3and CK2, although the significance of this phosphor-
ylation step remains unclear.132,133 Subsequent recruitment
and aggregation of Axin at the inner membrane leaflet via
an interaction between its C-terminal DAX domain and the
DIX domain of Dsh disrupts the b-catenin destruction com-
plex.134,135 LRP-5/6 contributes to disruption of the b-cat-
enin destruction complex as well by recruiting Axin to the
cell membrane. The intracellular domain of LRP-5/6 con-
tains five PPPSPxS motifs. Upon phosphorylation, which
occurs with Wnt signaling, the motifs become docking sites
for Axin (Fig. 2B).136,137 It is thought that recruitment of
Axin-GSK-3 by Fz and Dvl promotes phosphorylation of
PPPSPxS domains and facilitates further recruitment of Axin
in a ‘feed-forward’ or self-perpetuating manner.138,139 Axin
may interact with multiple PPPSPxS domains within the
same LRP-5/6 co-receptor or with domains on multiple re-
ceptors. The latter has been coined the ‘initiation-ampli-
fication’ model and leads to formation of LRP-5/6
aggregates.140
Two mechanistic models have been proposed for the
inhibition of b-catenin destruction by activation of the Fz/
LRP-5/6 receptor complex. In the first model, phosphory-
lated PPPSPxS directly binds and inhibits GSK-3.141,142 A
newer model proposes formation of a ‘multivesicular body’
(MVB) after binding of Wnt; GSK-3 is sequestered in MVBs,
thereby separating it from b-catenin. The model is based on
the work of Taelman et al, who demonstrated localization
of GSK-3 to acidic endosomal vesicles by fluorescence mi-
croscopy and protease protection studies.143Stable b-catenin accumulates and initiates transcription
of target genes promoting cell metabolism and
proliferation
Stabilization of b-catenin by Wnt signaling leads to propa-
gation of Wnt target gene transcription. In the absence of
Wnt signaling, members of the T-cell factor/lymphoid
enhancing factors (TCF/LEF) family of DNA-binding factors
are bound to the co-repressor protein Groucho, thereby
inhibiting transcription of their target genes.144 Following
LEF-1-facilitated nuclear translocation, b-catenin displaces
Groucho to create a transcriptional activator complex.145
Recruitment of purported co-activators, including the his-
tone acetyltransferases cyclic AMP response element-
binding protein (CBP) and p300 and the chromatin remod-
eling factor Brg1, induces chromatin remodeling to favor
gene transcription.146,147 Intra-nuclear regulation of Wnt
signaling occurs in part via sequestration or enzymatic
modification of b-catenin, TCF/LEF transcription factors,
and/or co-activator molecules.148
Target genes of Wnt signaling are recognized by TCF/LEF
transcription factors at a highly conserved binding element
composed of a consensus sequence (50-CTTTG[A/T][A/T]-
30) in the promoter region near the transcription start
site.149,150 Since the early identification of c-Myc and cyclin
D1 as Wnt/b-catenin downstream targets, numerous TCF/
LEF target genes have been reported.38e40,151e160 Many of
these genes encode gene products capable of broadly
upregulating cell proliferation and metabolism, as exem-
plified by the following three targets:
(1) The oncogene c-MYC, which encodes a transcription
factor whose target genes regulate processes
including cell proliferation (cyclin D2, CDK4, cyclin
B1), metabolism (enolase A, hexokinase II, lactate
dehydrogenase A, phosphofructokinase, and glucose
transporter), protein synthesis (genes encoding rRNA,
ribosome biogenesis proteins), cytoskeletal rear-
rangement (c-MYC overexpression has been shown to
decrease expression of collagen and integrin genes),
and apoptosis (E2F1, itself a transcription factor
promoting cell cycle progression and apoptosis, and
TRAP1, the tumor necrosis factor receptor associated
protein).106,161e163 Data from high-throughput
screens estimates the c-MYC gene network to
comprise approximately 15% of the genome from flies
to humans. Deregulation of c-MYC activity is one of
the most common alterations reported in human
malignancy.164 Recent studies indicate that c-MYC
may also regulate expression of long non-coding RNAs
in both normal and cancer cells, suggesting a unique,
novel route by which c-MYC may exert additional
control over the proliferation of both normal and
cancerous tissue.165,166
(2) CCND1, which encodes cyclin D1, a nuclear protein
required for cell cycle progression from G0/G1 to S
phase.152,153,167 Cyclin D1 functions as a regulatory
subunit of cyclin-dependent kinase-4 and -6 (CDK4,
CDK6). When bound to cyclin D1, CDK-4 and -6 phos-
phorylate and contribute to the inactivation of a cell
cycle inhibitor, retinoblastoma protein (pRb), thereby
facilitating cell cycle progression.168(p6) Cyclin D1 is
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during S phase, lending temporality to its activity.167
In vitro experiments using HEK 293 T cells demon-
strated a 2e3 fold increase in CCND1 expression when
cells were transfected with degradation-resistant
mutant N-terminal b-catenin constructs. A 10- to-
15-fold increase in induction of the CCND1 promoter
was observed in 293T and human neuroblastoma 2A
cell lines following transfection with the same
construct.153
(3) AXIN2, which is present in vertebrates and encodes
the Axin1 homologue Axin2. Like Axin1, Axin2 is a
negative regulator of canonical Wnt signaling; unlike
Axin1, it is not expressed constitutively.155,157 Its
expression pattern suggests that it may play a role in
regulating the duration or intensity of Wnt-initiated
signals.157 Axin2 has additionally been shown to
mediate the epithelialemesenchymal transition
(EMT) by regulating intra-nuclear activity of GSK-3b,
which is primarily responsible for modulating the
stability of a zinc finger transcription factor,
Snail1.169 Snail1 is a known transcriptional repressor
and a promoter of EMT when in complex with the
transcriptional modulators SMAD3/4.170(p1) While
appropriate activation of EMT facilitates critical steps
in embryological development and adult tissue heal-
ing by allowing epithelial cells to change phenotype
in response to developmental stimuli or stress, its
inappropriate activation is involved in initiation of
epithelial cancer cell metastasis.171
Wnt signaling is tightly regulated by naturally-
occurring extracellular antagonists
Inhibitors of Wnt signaling can be classified into two fam-
ilies e those that bind Wnt ligands directly and those that
regulate signaling by interacting with the Fz/LRP receptor-
co-receptor complex.
Direct binders sequester Wnt to inhibit Wnt
signaling
Secreted Fz-related proteins (sFRPs) exhibit homology to
Fz CRD and may have a biphasic effect on Wnt signaling
The discovery in mammalian cells of a family of five
secreted proteins homologous to the CRD of Fz and with the
ability to bind Wnt added another level of complexity to
Wnt signaling.172 Known as secreted Fz-related proteins
(sFRPs), they contain an N-terminal signal sequence, a Fz-
like CRD, and a C-terminal domain of conserved hydro-
philic residues. The sFRP-1 was shown to bind Wg, pur-
portedly though the C-terminus. While the CRD may still
play a role in optimizing binding capacity of sFRPs as it does
for Fzs, the C-terminus has been demonstrated to be
indispensable for sFRP to bind Wg.173 The C-terminal
portion has also been demonstrated to confer heparin-
binding properties, which may allow for extracellular co-
localization of sFRPs with secreted Wnt ligands. Heparin
was demonstrated to enhance sFRP-1-Wnt binding at
optimal concentrations.173 There is evidence to suggest
that there may be specificity to the binding interactions ofsFRPs and Wnt ligands. FrzA, a sFRP highly expressed in
mammalian vascular endothelium, has been shown to
associate with Wnt1, but did not demonstrate a binding
affinity for Wnt5a while another sFRP, Frzb-1, associated
with neither Wnt1 nor Wnt5a.174
These proteins have a putative negative regulatory ef-
fect on Wnt signaling. Upon binding Wnt1, FrzA was shown
to inhibit Wnt-1-mediated increases in cytoplasmic b-cat-
enin levels and transcription of a TCF/LEF reporter gene.174
However, in a Drosophila model, sFRP-1 demonstrated a
biphasic effect on modulation of Wg signaling as measured
by stabilization of Armadillo (Arm), the Drosophila homolog
of b-catenin. While high concentrations of sFRP-1 (>10 mg/
mL) blocked Wg activity, lower concentrations increased
concentrations of Arm. These effects were not observed in
the absence of Wg or in cells lacking DFz2 expression,
suggesting that sFRP-1 modulates an activity of Wg
dependent on its interaction with DFz2.173 Thus, although
their role is thought to be as a competitive inhibitor of
WnteFz binding, the effects of sFRPs on Wnt signaling are
varied and may depend on interactions with additional
binding partners. This remains to be evaluated further.175
Wnt-interacting factor (WIF) binds Wnt through an
N-terminal WIF domain
The Wnt-interacting factor WIF-1 was first discovered in
human retinal cells by Macke and colleagues and first
described in the literature by Hsieh et al as a secreted
protein overexpressed during Xenopus and zebrafish
development to control somitogenesis by modulating
spatial and temporal activity of Wnts.176
The structure of WIF-1 includes five epidermal growth
factor (EGF)-like repeats, a motif commonly found in
extracellular matrix (ECM) proteins, suggesting that WIF-1
is a secreted component of the ECM. The EGF-like repeats
are flanked by an approximately 150-residue N-terminal
domain known as the WIF domain, and an approximately
45-residue C-terminal hydrophilic domain.176,177 It is
thought to inhibit Wnt signaling by directly binding Wnt li-
gands at the WIF domain. Hsieh et al demonstrated co-
precipitation of Wg and the fusion protein XWnt8-Myc
(Wnt8 tagged with a C-terminal Myc epitope) by both
WIF-1-IgG and WD-IgG, an IgG fusion containing only the
WIF domain. XWnt8-Myc exhibits a similar binding affinity
for human WIF-1 (hWIF-1) and the CRD of DFz2. A 40-fold
excess of murine sFRP-3 had no effect on co-precipitation
of XWnt8-Myc and WIF-1-IgG.176 Taken together, these re-
sults suggest that at least two Wnt proteins, Wg and XWnt8-
Myc, non-covalently bind with high affinity to hWIF-1. In the
case of XWnt8-Myc, these experiments suggest that hWIF-1
and DFz2-CRD bind the fusion protein at sites that either
overlap or show negative cooperativity.176
Cerberus is an inhibitor of multiple signaling pathways,
including Wnt signaling
Cerberus is another secreted Wnt inhibitor discovered in
Xenopus as a transiently expressed protein with a role in
dorsal axis patterning.178 It is structurally similar to a
previously-discovered family of murine cystine-knot pro-
teins, the can family, which act as antagonists of trans-
forming growth factor b (TGF-b) and are known to play a
role in embryonic patterning and development.179e181 In
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inhibits bone morphogenetic protein (BMP) and Nodal
signaling. Binding of Xenopus Cerberus to Xenopus nodal-
related-1 (Xnr1) was not affected by excess BMP in
in vitro experiments by Piccolo et al, suggesting that
Cerberus binds each ligand at an independent site.182 In the
same study, proteolytically-processed isoforms of Xenopus
Cerberus (XCer) retained the ability to bind Xnr1 but were
unable to bind Wnt-8 and BMP-4, suggesting that proteolysis
of XCer may be used to regulate Wnt antagonist activity of
Cerberus.182Direct binders of the Fz/co-receptor complex can
inhibit or enhance canonical Wnt signaling
Dicckopf proteins bind to LRP-5/6 co-receptors to inhibit
Wnt signaling
The dickkopf (Dkk) family of proteins is comprised of 4
members (Dkk1-4) and was originally discovered to inhibit
Wnt-induced secondary-axis induction in Xenopus em-
bryos.183 Genetic evidence from both mammalian and
Xenopus cells demonstrates that Dkk-1 works upstream of
the destruction complex.183,184 Functional inhibition of Wnt
signaling by Dkk-1 is independent of Fz, but decreases with
increasing expression of LRP-6.183,184 Cross-linking experi-
ments have demonstrated formation of a complex between
Dkk-1 and LRP-6 with 1:1 stoichiometry. Taken together,
these results suggest that Dkk-1 functions as a specific in-
hibitor of canonical Wnt signaling by blocking the functional
interaction between Fz and LRP-6 required for transduction
of canonical Wnt signaling.183 Further experimentation in
Xenopus by Mao et al showed that this inhibition occurs by
Dkk-1 or -2 binding to a domain on LRP-6 separate from
those involved in the Wnt/Fz interaction.123
An expression screen for cDNAs mediating binding of
Dkk-1-alkaline phosphatase fusion protein identified two
transmembrane proteins, later named Kremen-1 and
Kremen-2. Cross-linking and co-immunoprecipitation ex-
periments identified both as high-affinity receptors for Dkk-
1 and -2, while bioluminescence resonance energy transfer
(BRET) experiments demonstrated formation of a ternary
complex between Dkk-1, Kremens, and LRP-6 in 293T cells.
Fluorescence data of cells transfected with krm2 revealed
localization of LRP-6 from the plasma membrane to endo-
cytic vesicles upon addition of Dkk1, indicating co-
internalization of the ternary complex. These experi-
ments suggest a mechanism for Dkk- and Kremen-mediated
inhibition of Wnt signaling, whereby interaction with the
LRP-5/6 co-receptor triggers endocytosis of the Wnt/LRP-
5/6 complex.185
Notably, DKK-1 can be induced by activation of canonical
signaling via Wnt1 or ectopic expression of active b-cat-
enin, TCF4, or LRP-6 mutants. The non-canonical Wnt
ligand Wnt5A does not appear to activate DKK-1. Analysis by
Northern and Western blot showed activation of the ca-
nonical pathway and increased DKK-1 RNA following co-
culture of 293T cells transfected with the DKK-1 promoter
and Rat2 cells stably expressing murine Wnt1 or Wnt5a.
Sequence analysis of the human DKK-1 promoter reveals
nine putative TCF-binding sites. Collectively, these resultssuggest that a negative feedback loop mediated by DKK-1 is
activated by and regulates canonical Wnt signaling.186
In addition, Dkk-2 has been demonstrated to function
alternately as a weak agonist or as an antagonist of Wnt
signaling.149,187 These results led to the postulate that an
unknown co-factor was responsible for converting Dkk-2
from an agonist into an antagonist of Wnt signaling; this
co-factor has since been demonstrated by Mao and Niehrs
to be Kremen-1/2.185,188(p2)
Sclerostin binds to LRP-5/6 to inhibit canonical Wnt
signaling
Sclerostin is an osteocyte-secreted antagonist of canonical
Wnt signaling encoded by the gene SOST, initially identified
as the gene whose loss leads to sclerosteosis, an autosomal
recessive condition marked by generalized hyperostosis and
sclerosis.189,190 SOST deficiency has also been identified in
van Buchem disease, a similar sclerosing disorder also
exhibiting autosomal recessive inheritance.191 Sclerostin
inhibits BMP-mediated bone formation, but unlike classical
BMP antagonists which bind BMP receptors, it inhibits Wnt
signaling.190,192 Li et al initially reported that sclerostin-
mediating antagonism of canonical Wnt signaling in
human and murine cell lines could be reversed by over-
expression of LRP5. They subsequently demonstrated that
sclerostin inhibits canonical signaling by binding LRP-5 and
LRP-6 at the PE domain (also referred to as the YWTD-EGF
domain).193 Although this domain is known to also bind
canonical Wnt ligands, the presence of Wnt3a did not
interfere with sclerostin binding to LRP-5.193
While structural characterization of sclerostin remains
limited, sequencing data for the 190-residue glycoprotein
predicts that it contains a cysteine-knot motif and is a
member of the DAN/Cerberus protein family.194 Docking-
based protocols used by Veverka et al identified a
heparin-binding site, suggesting that sclerostin may be
localized to the extracellular surface following secre-
tion.195 In the same study, N- and C-terminal arms were
found to be unstructured, highly flexible, and unaffected
by the binding of heparin, suggesting that they may
participate in stabilizing interactions with target proteins
such as LRP-5/6.195
R-spondins act as facilitators of Wnt signaling
The roof plate-specific spondins (R-spondins, RSpos) pro-
teins are a family of four Cys-rich secreted proteins (Rspo1-
4) which activate and regulate canonical Wnt signaling with
varying potency.57,196 RSpos share 40e60% sequence ho-
mology and similar organization of a set of conserved do-
mains; N-terminal Cys-rich furin-like domains are followed
by a common thrombospondin (TSP-1) motif.197,198 The
variation in potency of Wnt signaling activation observed
across the Rspos family has been attributed to variations in
furin-like domains.196 As with other components of Wnt
signaling, RSpos also exhibit direct orthology across
species.198
A link between RSpos and canonical signaling was first
implied by the spatial overlap observed between expression
of RSpos and Wnt in murine embryogenesis.199,200 Since
then, it has been demonstrated that RSpos compete with
Dkk-1 for binding to LRP-6, thereby reducing co-receptor
internalization.196,201 Although both antagonism of Dkk-1
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to furin domains, further experimentation is required to
causally link Dkk-1 antagonism to activation of Wnt
signaling.196
Norrin exhibits important but uncertain effects on Wnt
signaling
Norrin, alternatively known as Norrie Disease Protein 2, is
an atypical Wnt ligand encoded by the Norrie disease pro-
tein (NDP) gene. NDP was originally discovered by gene
mapping and positional cloning as the gene underlying
Norrie disease and familial exudative vitreoretinopathy
(FEVR), two disorders of congenital retinal
hypovascularization.202,203
Determination of Norrin’s function proved challenging,
as it exhibits limited homology with proteins of known
function and murine knockout models had a limited ability
to phenocopy the human condition.204 However, the dis-
covery that mutations underlying the autosomal dominant
variant of FEVR included those leading to loss of function of
the Wnt receptor Fz4 led to the subsequent identification
of Norrin as a ligand of Fz4 capable of activating canonical
Wnt signaling by binding with high affinity to Fz4-CRD.205,206
Demonstration by Nathans and colleagues that Norrin does
not bind with CRDs of other Fzs, established Fz4 as a spe-
cific receptor for Norrin.206
Although LRP-5/6 is necessary for activation of canonical
signaling by Norrin, earlier data from cell-binding assays
showed no direct interaction between Norrin and LRP-5/
6.206 Since then, however, Ke et al have demonstrated
binding between Norrin and LRP-5/6 by AlphaScreen assay
as well as ternary complex formation between Norrin and
LRP-6.207 TSPAN12, a member of the tetraspanin family of
transmembrane proteins, is also a member of the Norrin-
Fz4 receptor complex and is required for Norrin-mediated
Fz4 signaling. Loss of TSPAN12 was not shown to affect
Wnt-mediated Fz4 signaling.208(p12)
Although Norrin is a Cys-rich protein, it exhibits limited
structural similarity to Wnt ligands and is instead part of
the Cys knot superfamily, exhibiting w17% sequence ho-
mology with the growth factor TGF-b. It forms a unique
dimer interface that is required for it to signal through
Fz4.207
The discovery of the Norrin-Fz4 interaction places a dent
in the paradigm that Fzs are dedicated receptors for Wnt
ligands and creates the possibility of studying activation-
related changes in Fz structure e a task made difficult in
the past by the challenge of isolating active Wnt ligands.204Wnt signaling regulates stemness and
progenitor cell renewal in diverse tissue types
The Wnt signaling cascade has been identified as a regu-
lator of self-renewal and proliferation among a variety of
stem and progenitor cell populations.209 Supporting evi-
dence demonstrating the critical role that Wnt plays in
maintaining stem cell populations comes in part from
studying the renewal of a range of tissue types, including
intestinal epithelium, skeletal tissue, hematopoietic
cells, and the hair follicle. Wnt signaling has also been
shown to be capable of maintaining the transcriptionalprofile of pluripotent stem cells and has been found to be
active in a more recently proposed class of progenitor
cells implicated in tumorigenesis e cancer stem cells
(CSCs).
Embryonic/pluripotent stem cells
In contrast to tissue- or organ-specific multipotent stem
cell populations, embryonic stem cells derived from the
inner cell mass (ICM) of the blastocyst are pluripotent,
retaining the ability to differentiate into any cell type (with
the exception of placental tissue).210 Maintenance of plu-
ripotency is dependent on a combination of epigenetic,
transcriptional, and post-transcriptional mechanisms,
including evolutionarily conserved pathways such as ca-
nonical Wnt signaling. Activation of Wnt signaling was
shown by Sato et al to be sufficient for maintaining plu-
ripotency in both murine and human embryonic stem cells
(MESCs, HESCs). Expression of pluripotency-specific tran-
scription factors Oct-3/4, Rex-1, and Nanog were main-
tained when both types of ESCs were treated with 6-
bromoindirubin-30-oxime (BIO), a pharmacologic specific
inhibitor of GSK-3. The effects were reversible; removal of
BIO from culture medium led to physiologic differentiation
in both ESCs.211 Miyabayashi et al reported similar results,
demonstrating that the small molecule inhibitor IQ-1 pre-
vents spontaneous differentiation of MESCs by activating
Wnt signaling. However, their work illustrates that Wnt-
based maintenance of pluripotency is dependent on acti-
vation of b-catenin/CBP-mediated transcription at the
expense of b-catenin/p300-mediated transcription. IQ-1
was shown to specifically promote this transcription pro-
gram by targeting a subunit of PP2A and thereby prevent-
ing, by an unknown mechanism, phosphorylation of p300 at
Ser-89, a modification known to enhance its binding inter-
action with b-catenin.212
In addition to maintaining pluripotency, Wnt signaling
has also been shown to be capable of reprogramming plu-
ripotency in somatic cells. Although these cells, termed
induced pluripotent stem (iPS) cells, have previously been
generated by introduction of pluripotency-promoting tran-
scription factors Oct4, Sox2, Klf4, and c-Myc via retroviral
transduction, the increased risk of tumorigenesis from
infection with c-MYC retrovirus is a limitation to use of this
technique in regenerative medicine.213e215 Retroviral
transduction of the remaining three has not been shown to
produce pluripotency with similar efficiency.216 Work by
Marson et al circumvents this concern by demonstrating
that soluble Wnt3a is capable of producing pluripotency in
the absence of c-Myc retrovirus. Murine fibroblasts infected
with doxycycline-inducible Oct4, Sox2, and Klf4 lentiviruses
and grown in Wnt3a-conditioned medium (Wnt3a-CM) grew
into colonies resembling the morphology of ESCs and iPS
cells. When combined with results of immunocytochemistry
and functional assays, Wnt3a-CM iPS cells were not
discernable from ESCs.217
Intestinal stem cells
The basic unit of the intestinal epithelium is the villuse-
crypt complex, consisting of a villus, or finger-like
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basal crypts, or depressions. Intestinal villi are lined with a
specialized absorptive epithelium that is distinctive, even
among epithelial tissues, for a remarkable turnover rate. A
population of stem cells residing at the base of surrounding
crypts generates progenitor cells to constant replace
epithelial cells as they apoptose at the villus tip. Progenitor
cells arrest mitosis and differentiate into intestinal
epithelial cells upon reaching the cryptevillus junction.209
Current evidence suggests canonical Wnt signaling as
the signal controlling differentiation of crypt stem cells
into absorptive epithelial cells. Nuclear localization of b-
catenin, the hallmark of canonical Wnt signaling, is
observed throughout intestinal crypt cells. b-Catenin and
TCF have previously been shown to inversely control
expression of the cytoskeleton-modifying receptors
EphB2/EphB3 and their ligand, ephrin-B1, thereby
coupling cell proliferation and differentiation to move-
ment along the crypt axis.218 Mice with homozygous loss of
TCF4 have been observed to be born with normal villous
epithelia, but with loss of crypt progenitor cells.219 Inhi-
bition of Wnt signaling by transgenic expression of Dkk-1 in
adult mice leads to a similar phenotype with loss of crypts.
Inappropriate expression of the b-catenin/Tcf-4 complex
among colorectal cancer cells lineages has been shown to
maintain a progenitor cell phenotype. Disruption of b-
catenin/Tcf-4 in these lineages leads to cell cycle arrest in
G1 and differentiation.220Hematopoietic stem cells
Among hematopoietic stem cells (HSCs), multiple pathways
underlying key aspects of development e Notch, Hedgehog,
and Wnt e are thought to play a role in self-renewal and
maintenance of stem cell and progenitor cell pop-
ulations.221e223 Wnt signaling in particular is thought to
function in an autocrine or paracrine manner to maintain
HSC phenotypes. Studies of both murine and human cell
lines demonstrate expression of various Wnt ligands by
hematopoietic cell lineages and by stromal cells.223 The
significance of this pathway in proliferation of HSCs was
demonstrated by Reya et al, who showed that silencing of
Wnt signaling by ectopic expression of a Fz ligand-binding
domain or Axin inhibits in vitro growth and in vivo regen-
eration of HSCs.224 Willert et al showed reconstitution of
HSC lineages in lethally irradiated mice injected with
Wnt3A-treated HSCs.20 By contrast, In vitro functional as-
says demonstrate that soluble Wnt proteins synergize with
the CD117 ligand steel factor in murine hematopoietic
progenitor cells to inhibit differentiation and promote
replication.225
A mechanism for these results is suggested by the work
of Willert et al, who demonstrated that activation of Wnt
signaling in hematopoietic stem and progenitor cells in-
creases in vitro expression HoxB4 and Notch1, genes known
to play a role in HSC self-renewal.224 While the canonical
Wnt signaling pathway is thought to be responsible for
maintenance of intestinal crypt cells, among HSCs, both
canonical and non-canonical Wnt ligands have been found
to control HSC renewal. Further study is required to
determine which pathway predominates.209Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are a multi-potent subset of
non-hematopoietic cells in the stroma of bone marrow and
adipose tissue capable of differentiating into a multitude of
cell lineages, including osteoblasts, chondrocytes, adipo-
cytes, tenocytes, and hematopoiesis-supporting stromal
cells.226e228 Canonical Wnt signaling has been shown to play
a critical role in regulating cell fate decisions of MSCs;
activation of canonical Wnt signaling promotes osteogenic
differentiation of MSCs by upregulating the expression of
Cbfa1/Runx2, a transcription factor known to activate the
program of osteoblastogenesis, and of alkaline phospha-
tase, a marker of osteoblastic differentiation.229,230 When
combined with osteogenic bone morphogenetic proteins
(BMPs), canonical Wnt/b-catenin signaling was shown to
induce overlapping target genes and to act synergistically
to induce osteogenic differentiation of
MSCs.159(p1),160,231,232 Conversely, the absence of canonical
Wnt signaling has been shown to promote an adipogenic
lineage. Activation of b-catenin via ectopic expression of
Wnt1 was shown to directly suppress expression of the
adipogenic transcription factor peroxisome proliferator-
activated receptor g (PPARg) and prevent adipogenic dif-
ferentiation of 3T3-L1 cells.233 Blocking Wnt/b-catenin
signaling has also been shown to enhance MSC-based
granulation tissue formation and peri-infarct myocardial
repair.234Musculoskeletal tissue
Skeletal tissue homeostasis relies on a balance between
osteoblast-mediated bone deposition and osteoclast-
mediated resorption. Changes in bone density can be
explained by an imbalance of activity between the two cell
types. The association of increased bone density with gain-
of-function mutations in LRP5 was an initial clue that Wnt
signaling may play a regulatory role in bone homeo-
stasis.235e237 Babij et al reported that transgenic mice
expressing human LRP5 G171V, a gain-of-function mutation
associated with high bone mass in two independent human
kindreds, exhibited dramatic increases in volumetric bone
mineral density and osteoblast activity.235,238 In addition,
loss of function mutations in SOST are known to lead to
sclerosteosis, a disease characterized by the development
of high bone mass.193,239
Glass et al reported a mechanism for the direct rela-
tionship of canonical Wnt signaling with bone density. They
initially demonstrated that stabilization of b-catenin in
differentiated osteoblasts leads to pathologically increase
bone mass, or osteopetrosis, while loss of b-catenin leads to
osteopenia. Surprisingly, histological analysis revealed that
the mutations in b-catenin were influencing bone resorp-
tion rather than bone deposition. Subsequent experiments
revealed that b-catenin and TCF proteins modulate
expression of Osteoprotegerin, which encodes the
osteoclastogenesis-inhibiting decoy receptor osteoprote-
gerin (OPG), was specifically identified as a target gene of
the b-catenin/TCF complex.240
While the above results suggest that canonical Wnt
signaling plays a pivotal role in bone homeostasis by
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Wnt signaling has been shown to distinctively regulate MSCs
in a biphasic manner depending on signal intensity. The
proliferation and self-renewal of MSCs were promoted only
under low levels of Wnt/b-catenin, whereas osteogenic
differentiation was promoted under high levels of Wnt
signaling.241
Hair follicles
Hair follicles are an additional site characterized by self-
renewal and continuous growth containing a population of
self-renewing multipotent stem cells.242 Known as ‘bulge
stem cells’ for the bulge they form in a contiguous portion
of the outer root sheath, these cells are located at the
inferior-most permanent portion of the hair follicle.243
Following activation, bulge stem cells proliferate rapidly
and form a hair germ which extends downward through the
outer root sheath to surround the dermal papilla, a
collection of specialized mesenchymal cells at the base of
the follicle. A matrix of proliferative cells, known as transit
amplifying cells, forms at the base and terminally differ-
entiates to produce the inner root sheath and the hair shaft
itself.244,245
Canonical Wnt signaling has been shown to be critical for
establishment and maintenance of the hair follicle. A
LEF1/ murine model was reported to have, among other
defects, a deficiency of hair follicles.246 Transgenic over-
expression of Lef-1 and stabilized, ‘oncogenic’ b-catenin
have been shown to induce de novo hair follicle growth, a
process normally found only in embryonic skin, in adult
murine models.247,248 Lowry et al performed functional
analyses and reported that b-catenin-mediated activation
of Lef1/Tcf complexes leads to upregulation of target genes
that include several that promote conversion and prolifer-
ation of transit amplifying cells into activated cells of
newly-developing hair follicles.245 Their work is supported
by the earlier findings of Huelsken et al, who reported that
b-catenin is essential for differentiation of bulge stem
cells; in its absence, stem cells adopt an epidermal
phenotype rather than differentiating into follicular
keratinocytes.249
Of note is that several hair keratin genes have been
identified among the target genes of b-catenin and Lef1,
somewhat paradoxically suggesting that in addition to
controlled the expansion of precursor cells, canonical Wnt
signaling plays a role in its terminal differentiation.244,247
Cancer stem cells
One of the defining characteristics of stem cells, self-
renewal, can be used to draw a parallel with cancer cells.
There is increasing evidence to suggest that among the
array of cells occupying a tumor there exists a subset of
self-renewing cells driving tumorigenesis, referred to as
cancer stem cells (CSCs). These cells may derive from stem
cells or rely on a similar set of pathways to drive self-
renewal.250
Given the critical role that Wnt signaling has been shown
to play in stem cell proliferation (reviewed above) and inoncogenesis (reviewed below), it has been proposed as a
pathway critical to the development and renewal of cancer
stem cells. In support of this hypothesis is the fact that
many surface markers used to identify and isolate putative
CSC populations from a broad range of primary tumor tis-
sues, including LGR5/GPR49, CD44, CD24, and Epcam, are
themselves Wnt target genes.251e255 LGR5-expressing
breast cancers exhibit CSC-like properties, including the
formation of self-renewing spheres and high tumorige-
nicity, due to activation of Wnt/b-catenin signaling and are
associated clinically with increased recurrence and poorer
outcomes.256 Activation of canonical signaling by Wnt3a
was shown to promote the self-renewal of cancer stem/
progenitor cells in acute lymphocytic leukemia and pros-
tate cancer.257,258 In the human colon cancer cell line LT97,
nuclear expression of b-catenin was observed with CD44þ
cells, but not in CD44 cells.259 While this evidence is
certainly compelling, further studies are needed to char-
acterize what difference, if any, there are between Wnt-
mediated regulation of normal stem/progenitor cells and
of CSCs.Abnormalities in Wnt signaling play a role in
select disorders of human development
As is the case for many evolutionarily conserved pathways
underlying critical processes in development, growth, and
metabolism, abnormal Wnt signaling has been implicated in
development and progression of human disease. Broadly
speaking, the two most common forms of disease associ-
ated with Wnt signaling include congenital disorders and
cancer, caused by aberrant signaling during early stages of
development or by inappropriate activation of signaling in
adults, respectively.260e264Loss of Wnt signaling can cause in utero
developmental malformation
Murine and Drosophila Wnt knock-out models exhibit a
diverse range of phenotypes due to loss of critical devel-
opmental steps. It follows that loss of Wnt function in
humans would have similarly dire consequences. Niemann
et al reported loss of WNT3 function by a homozygous
nonsense mutation as the cause of tetra-amelia, a disorder
characterized by loss of all four limbs.265 Their discovery
was the first to report the association of a WNT gene mu-
tation with a Mendelian disorder.Wnt signaling defects can cause neurodevelopmental
abnormalities
As part of its role in controlling aspects of embryological
development such as body patterning, Wnt signaling is
increasingly implicated in key aspects of neural develop-
ment.266 Although reviewed more thoroughly elsewhere by
Freese et al, we present here a brief review of neuro-
developmental abnormalities in humans which have been
linked to abnormalities in Wnt signaling.266
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multiple components of Wnt signaling.266 Dvl2 was shown to
be necessary for neural tube closure in murine models by
Hamblet et al. Mice with homozygous null mutations in Dvl2
developed thoracic spina bifida, while those with loss of
both Dvl1 and Dvl2 presented with a more severe disease
phenotype.267 Murine models have also shown that muta-
tions in axin and LRP6 can lead to NTD, with the latter also
being folate-responsive.90,268
Finally, accruing evidence suggests a role for Wnts in the
development of Williams Syndrome, a neurodevelopmental
disorder characterized by a lowered seizure threshold,
impaired spatial cognition, enhanced language abilities,
effusive personality, and preserved social function.269 Wil-
liams Syndrome is caused by a heterozygous microdeletion
of approximately 20 genes on chromosome 7, including the
gene for Fz9.270 It is likely that some cognitive defects in
Williams Syndrome are due to loss of Fz9. Zhao et al re-
ported that mice with null mutations of FZD9 exhibit neu-
rodevelopmental defects, including decreased visuospatial
memory and a lowered seizure threshold, while those with
loss of one allele have an intermediate presentation similar
to Williams Syndrome.271Abnormalities in canonical Wnt signaling are
frequently implicated in tumorigenesis
Abnormalities in canonical signaling leading to tumorigen-
esis are the most commonly-reported link between Wnt
signaling and disease. The discussion will be grouped into
Wnt ligand-independent and Wnt ligand-dependent mech-
anisms for abnormal activation of the canonical pathway
leading to tumorigenesis.
Wnt ligand-independent pathways for
tumorigenesis are most commonly found in
gastrointestinal carcinomas
Increased expression of Fz receptors is found in select
gastrointestinal carcinomas
Increased expression of Fz has been demonstrated in
gastrointestinal carcinomas. Upregulation of Fz under-
standably leads to increased activation of Wnt signaling but
has been demonstrated in only select tumor types, pri-
marily gastrointestinal carcinomas. Human FzE3 was iden-
tified as a gene expressed specifically in human esophageal
carcinoma cell lines, especially those with poorly-
differentiated histology, and has since been identified in
cases of gastric carcinoma as well.272,273 Expression of FzE3
in cases of gastric carcinoma was associated with accu-
mulation of b-catenin or with upregulation of CCND1
expression.273 Human FZD7 shares 98.8% sequence identity
with FzE3 and was found by Kirikoshi et al to be overex-
pressed in one gastric cancer cell line (MKN7) and one of six
gastric cancer samples tested.274 Finally, overexpression of
FZD10 has been demonstrated in 2 cases of primary colon
cancer by Terasaki et al.275 In the same study, they
demonstrated that Fz10 works synergistically with select
classes of Wnt ligands in upregulating canonical
signaling.275Loss of APC function by nonsense mutation or promoter
hypermethylation is commonly implicated in tumorigenesis,
especially of colorectal adenocarcinomas
Although the gene for Wnt1 was first discovered as the
target of an oncogenic retrovirus in a murine breast cancer
model, the connection between dysregulation of canonical
Wnt signaling and development of cancer was first estab-
lishedw10 years later. In their landmark work which led to
proposal of the adenoma-carcinoma sequence for stepwise
accumulation of genetic alterations facilitating colorectal
tumorigenesis, Vogelstein et al proposed biallelic loss of
APC as the first step in the development of inherited (e.g.,
through familial adenomatous polyposis) and up to 85% of
sporadic cases of colorectal cancers.11,12 Loss of APC
function leads to unregulated proliferation of intestinal
epithelial cells and formation of an adenoma, a benign
lesion.276 Stepwise accumulation of mutations in genes
including KRAS and TP53 is required for malignant
transformation.277
Point mutations in APC are seldom sufficient for causing
loss of APC function. Development of a cancerous pheno-
type requires loss of entire domains and the functionality
they confer upon the full-length protein. While most
tumorigenic APC nonsense mutations are located in the 50
half of the sequence, the spread of mutation loci varies
between hereditary and sporadic colorectal cancers.
Nagase and Nakamura demonstrated that germline
nonsense mutations in APC are distributed throughout the
50 region of the gene, while approximately two-thirds of
sporadic mutations map to a narrow region termed the
Mutation Cluster Region (MCR), spanning 8% of the coding
sequence (codons 1286-1513).278,279 The position at which
APC nonsense mutations occur and, hence, the size of the
truncated protein, can be correlated to disease severity.
Yang et al have demonstrated that truncations of APC which
retain the three 15-amino acid repeats and one or two of
the 20-amino acid repeats are associated with a more
aggressive tumor phenotype; more attenuated tumor phe-
notypes develop with loss of all b-catenin regulating do-
mains.106 Nonetheless, an attenuated FAP phenotype has
been reported in association with a chain-terminating mu-
tation in the 30 end of APC.106,280
To explain these and similar results, Propping and col-
leagues proposed a model linking the size of the APC
mutant to disease severity in which mutations occurring 50
to codon 157 or 30 to codon 1597 are associated with an
attenuated FAP phenotype.281 These mutations fail to
preclude the formation of stable dimers with preserved
binding interactions. Mutations occurring 50 to codon 157
create a fragment too short for stable dimerization,
thereby allowing a relatively large amount of stable, wild-
type homodimer to be formed. When the mutation occurs
30 to codon 1597, the fragment is capable of forming stable
heterodimers with full-length protein. These heterodimers
maintain correct conformation at the b-catenin binding
site. In both cases leading to the attenuated phenotype, a
so-called ‘second hit’, or mutation in the second copy of
APC, is required for polyp formation. This follows with
Knudson’s two-hit hypothesis requiring biallelic inactivation
for tumor suppressor genes such as APC to lose their func-
tion.282,283 Mutations occurring between codons 168 and
1578 lead to a more severe disease phenotype, or a typical
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mutant effect; they are able to form a stable heterodimer,
but do not retain the ability to correctly associate with b-
catenin. The loss of APC function occurs simultaneously and
across all epithelial cells.281 These mutations do not require
a second hit for expression of the disease phenotype.
The adenoma-carcinoma sequence is the pathway un-
derlying development of traditional (non-serrated) ade-
nomas (TAs), the precursor lesions for approximately 60% of
colorectal carcinomas. Another 35% arise from sessile
serrated adenomas (SSAs), which develop via the ‘serrated
pathway’, a separate set of stepwise alterations that are
often characterized by microsatellite instability.284,285
However, abnormal Wnt signaling has more recently been
implicated in their development as well. Yachida et al
demonstrated nuclear accumulation of b-catenin in 35 of 54
(67%) SSAs and in all 27 (100%) SSAs with evidence of
epithelial dysplasia. Although mutations in CTNNB1 capable
of causing abnormal b-catenin accumulation were not
identified, earlier work by Fu et al suggests a possible
mechanism.286 In a subset of the SSAs they analyzed (5/12,
41.7%) the canonical Wnt pathway was moderately acti-
vated by aberrant hypermethylation of APC promoter 1A.287
Thus, Wnt activation apparently plays a role in develop-
ment of both TAs and SSAs, albeit by different mechanisms.
Although APC-inactivating mutations are most commonly
associated with colorectal tumors, they have been reported
among other tumor types as well. Despite being the most
common cancer worldwide, carcinogenesis of gastric can-
cer remains poorly understood. Given that some gastric
cancers are thought to arise from intestinal metaplasia,
Nakatsuru and Horii evaluated gastric cancers for the
presence of nonsense mutations in APC.288 Upon examina-
tion of a region corresponding to 30% of the APC coding
sequence, including the MCR, in 57 sporadic gastric can-
cers, they identified mutations in 41% of very well-
differentiated adenocarcinomas, 11% of well- or
moderately-differentiated adenocarcinomas, and 30% of
signet-ring cell carcinomas. Mutations were not found in
poorly-differentiated adenocarcinomas.289 Likewise,
Ebert et al reported finding APC mutations at a higher rate
among intestinal-type gastric cancers than in diffuse-type
gastric cancers.290 The results of both studies suggest that
mutation of APC may contribute to tumorigenesis of
intestinal-type gastric cancers.
Among endometrial carcinomas, mutations of APC and b-
catenin have primarily been studied among the most com-
mon type, endometrioid endometrial carcinoma
(EEC).291,292 Although nuclear accumulation of b-catenin
has been detected among EECs, it is in association with
missense mutations in b-catenin (see below), not with
truncating mutations of APC.293e295 Palacios and colleagues
did, however, report methylation of the APC promoter 1A
occurring more frequently among EECs relative to NEECs.291
Mutations in APC have been shown to occur on occasion
in breast adenocarcinoma as well. Schlosshauer et al
screened twenty-four human breast cancer cell lines and
found a novel APC mutation, E1577stop, in one cell line (DU
4475). The mutation was associated with cytosolic accu-
mulation of b-catenin.296 Jo¨nsson et al found a 13% rate of
b-catenin accumulation among 54 primary breast tumors
screened for abnormalities in APC/b-catenin signaling. APCwas altered in 6% of tumors, and no samples contained
mutations in the N-terminal region of CTNNB1. While 9% of
tumors demonstrated upregulation of c-MYC, it did not
correlate with b-catenin accumulation.297 Taken together,
these results suggest that dysfunction of APC likely plays a
limited role in breast carcinogenesis.
Loss of Axin function is found in hepatocellular and
colorectal cancers
Loss of Axin has been demonstrated in cell lines and patient
samples from hepatocellular and colorectal cancers. Mu-
tations in AXIN1 were demonstrated by Satoh et al in 3 of 4
cell lines and 5 of 87 primary hepatocellular carcinoma
(HCC). Cells with AXIN1 mutations additionally demon-
strated cytosolic accumulation of b-catenin on IHC and
increased nuclear binding of b-catenin-associated TCF
transcription factors to DNA.298
AXINmutations appear to play a role in development of a
subset of colorectal cancers, specifically those with defects
in mismatch repair. Liu et al demonstrated frameshift mu-
tations in AXIN2 and corresponding loss of Axin function in
11/45 colorectal cancer tumors with defective mismatch
repair. All 11 mutations were found to disrupt the DIX
domain, which is necessary for homo-oligomerization in the
AXIN2 homologue Axin.299 An alternate mechanism by
which AXIN mutations may preclude b-catenin destruction
was demonstrated by Webster et al who identified two
heterozygous AXIN1 sequence variants. One of these mu-
tations, L396M, was found in multiple colorectal cell lines
and was shown by gene mapping as well as biochemical and
functional studies to interfere with the ability of Axin to
bind GSK-3b.300
Prostaglandin E2 is a potent mitogen in colon cancer cell
lines with homozygous loss of APC. PGE2 has been shown to
stimulate b-catenin-mediated transcription by disrupting
the Axin-GSK-3b interaction. Upon binding to its GPCR, EP2,
PEG2 activates a signaling route involving direct association
of the G protein as subunit with Axin and subsequent
release of GSK-3b from the b-catenin destruction
complex.301
Mutations stabilizing b-catenin can substitute for
upstream aberrations of Wnt signaling
Increased levels of free b-catenin can occur directly from
stabilizing, or activating, mutations in CTNNB1. Exon 3,
specifically the NH2-terminal regulatory domain, encodes a
sequence of conserved Ser/Thr residues and has proven to
be a mutation hotspot. Mutations in this location activate
constitutive Wnt signaling by precluding GSK-3b-mediated
phosphorylation of the Ser/Thr residues, thereby prevent-
ing formation of a b-TrCP binding site.302 These mutations
have been identified frequently across tumor types.
In the case of colon adenocarcinoma, although the
overwhelming majority of cases develop following mutation
of APC (reviewed above), Sparks et al report that approxi-
mately half (48%) of colon adenocarcinomas with wild-type
APC have an activating mutation in CTNNB1 and that mu-
tations in APC and CTNNB1 are mutually exclusive.303 The
latter finding supports the two sets of mutations having
equivalent effects on b-catenin stability, suggesting that
CTNNB1 activating mutations may substitute for loss of APC
function in colon carcinogenesis.
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vating mutations have been reported most frequently in
association with hepatocellular carcinoma (HCC). Miyoshi
et al found somatic CTNNB1 mutations in 14 samples from a
screen of 75 primary HCC samples. Of the 14, eight were
either deletions in exon 3 or missense mutations altering
the regulatory Ser/Thr residues. The remaining tumors
contained mutations at codons neighboring a conserved Ser
residue.304 In their analysis of human HCC samples, de la
Coste et al report a similar rate; eight of 31 samples (26%)
contained point mutations or deletions in CTNNB1 leading
to dysregulation of b-catenin.305 Of note is that a lower rate
of has been seen in cases of aflatoxin-associated HCC, as
reported by Devereux et al. Although 20 of the 62 HCC tu-
mors from individuals exposed to aflatoxin B1 showed
strong staining on IHC for b-catenin, CTNNB1 mutations
were identified in only 5 (12.2%), suggesting that the
observed b-catenin accumulation in aflatoxin-associated
HCC may be due to mutation in another component of
Wnt signaling.306
Among ovarian carcinomas, activating mutations of
CTNNB1 have been reported among the endometriod sub-
type. In a study of 40 stage I and stage II ovarian border-
line tumors and carcinomas, five out of six endometriod
lesions exhibited nuclear localization of b-catenin on IHC.
Three of the endometriod lesions, including one borderline
tumor and two carcinomas, were heterozygous for missense
mutations in CTNNB1 and were confirmed to have abnormal
b-catenin expression. The results suggest that CTNNB1
mutations may play a role in ovarian tumorigenesis and may
characteristically give rise to the endometriod pheno-
type.307 Their results are supported by later work of Wright
et al, who reported finding activating mutations of b-cat-
enin among 10 of 63 (16%) of endometriod ovarian tumors
analyzed. All mutations were missense mutations in the
GSK-3b consensus site and were confirmed by IHC to be
associated with nuclear localization of b-catenin.308
Abnormal localization of b-catenin has been reported in
thyroid carcinomas on multiple occasions and even associ-
ated with the aggressive behavior of the anaplastic sub-
type.309e311 In a study of 145 thyroid tumor samples
collected from 127 patients, reduced membrane localiza-
tion of b-catenin was observed among all 115 thyroid car-
cinomas analyzed and found to be associated with
progressive loss of tumor differentiation, a known indicator
of poor prognosis. Mutational analysis revealed that muta-
tions in CTNNB1 were found exclusively in poor-to-
undifferentiated tumors; 25% of poorly-differentiated and
65.5% of undifferentiated carcinomas contained exon 3
mutations. In addition to identifying b-catenin dysregula-
tion as a pathway in development or progression of thyroid
carcinomas, these findings suggest that b-catenin expres-
sion patterns and mutational analysis may be a clinically-
relevant tool for subtyping thyroid carcinomas and for
predicting disease outcomes.312
Mutations in exon 3 of CTNNB1 have also been found in
the cribriform-morular variant of papillary thyroid carci-
noma (CMV-PTC), a rare subtype of PTC. Although most
commonly diagnosed as an extra-colonic manifestation of
FAP, CMV-PTC can occur sporadically as well. Xu et al
evaluated five CMV-PTC tumors, including both sporadic
and FAP-associated cases. Nuclear accumulation of b-catenin on IHC and somatic mutations in exon 3 of CTNNB1
were observed in all five cases. Although germline APC
mutation was observed in one of the two FAP-associated
cases, loss of heterozygosity was not observed.313Epigenetic silencing of Wnt signaling inhibitors
Upregulation of Wnt signaling in tumorigenesis has also
been shown to occur secondary to downregulation of Wnt
signal inhibitors, most commonly by epigenetic modifica-
tions. These changes have also been found, in select can-
cers, to be prognostic indicators. Screening tests for these
changes in said cancers may therefore be a clinically-
relevant prognostic tool.
sFRPs are epigenetically silenced in some human cancers
Promoter hypermethylation of SFRP1 in human colorectal
cancer was first reported by Suzuki et al following a screen
of 10,000 candidate genes by cDNA microarray analysis.
Their microarray strategy combined gene expression status
with epigenetic regulation to identify genes with hyper-
methylated promoters in a colorectal cancer cell line, RKO.
Three other genes belonging to the same family as SFRP1,
SEZ6L, KIAA0786, and CXX1, also demonstrated promoter
hypermethylation in RKO cells. Similar results were ob-
tained in primary colorectal cancer tissues. Promoter
hypermethylation of all four genes was subsequently eval-
uated in other colorectal cancer cell lines, as well as in cell
lines of gastric, breast, lung, liver, and prostate cancers.
Promoter hypermethylation of these genes was largely
observed only in colorectal and gastric cancer cell lines,
suggesting that comprehensive marker panels with these
genes may have diagnostic utility in identifying colorectal
and gastric cancers.314
Suzuki et al also investigated methylation and expres-
sion of other SFRP family members, (SFRP2-5) and found
that three are frequently hypermethylated in colorectal
cancer cell lines. These three, SFRP2, 4, and 5, were also
found to be methylated in primary colorectal tumors. Of
the 124 patients samples, 30 (24.1%) demonstrated pro-
moter methylation of four SFRP genes (1, 2, 4, and 5).
Nojima et al investigated silencing of the SFRP gene
family among gastric cancer cell lines and primary tumor
samples. They reported that promoter hypermethylation of
SFRP1, 2, and 5 occurs frequently among gastric cancer cell
lines and primary tumor samples. Promoter hyper-
methylation of SFRP1, 2, and 5 was observed in 16 (100%),
16 (100%), and 13 (81%) cell lines, as well as 42 (91%), 44
(96%), and 30 (65%) primary tumor samples. Ectopic
expression of SFRP1, 2, and 5, suppressed TCF/LEF activity
in three gastric cancer cell lines with constitutively active
Wnt signaling. Changes in gene expression profiles by
overexpression of SFRPs were evaluated using SFRP2 and
the colon cancer cell line SNU638, which has high TCF/LEF
activity. Four Wnt target genes, LEF1, MMP7, cyclin D1, and
CD44 were found to be downregulated by ectopic SFRP2
expression. These results support SFRP silencing as a com-
mon event in gastric cancer and as a potential therapeutic
target.315
Although infection with human papilloma virus (HPV) is
most significant risk factor associated with cervical cancer,
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Increased cytoplasmic and nuclear localization of b-catenin
have been observed in samples of invasive cervical carci-
nomas, indicating that there may be a role for canonical
Wnt signaling in disease progression.316 Chung et al report a
possible mechanism for the observed dysregulation of ca-
nonical Wnt signaling; they identified promoter hyper-
methylation of SFRP1, 2, and 4 in cervical lesions, with
increased frequency in tumors relative to in situ lesions.
Their results support the potential use of these genes as a
screening tool for cervical carcinogenesis in precursor le-
sions. Of note, promoter methylation of SFRP5 was signifi-
cantly decreased in patients without lymph node
metastases.317
In the case of bladder cancer, SFRP promoter hyper-
methylation has been found to be a predictor of invasive
disease and, thus, a prognostic indicator. In a population-
based study of 355 individuals, Marsit et al found a linear
relationship between the number of methylated SFRP genes
and risk for invasive cancer. Promoter methylation of any
SFRP gene was independently associated with overall
poorer survival (hazard ratio 1.78). When SFRP methylation
was present along with mutation of the tumor suppressor
gene TP53, the risk for invasive disease was greater than
30-fold. These results suggest that promoter methylation of
SFRP genes may be a powerful tool for predicting the
development of an invasive phenotype in bladder cancer.318
Down-regulation of WIF is found in some human cancers
Down-regulation of genes encoding WIF across multiple
tumor types was first demonstrated by Wissmann et al in a
study designed to detect novel Wnt pathway genes involved
in tumorigenesis. Chip hybridization of microdissected
matched pairs from 54 primary prostate carcinomas iden-
tified multiple Wnt pathway genes with differential
expression. Of these, WIF1 and SFRP4 showed the most
significant aberrant expression e expression of WIF1 was
down-regulated in 64% of samples while expression of
SFRP4 was up-regulated in 81%. IHC of primary tissues
showed a strong reduction in WIF-1 protein expression
among 23% of prostate carcinomas, 60% of breast adeno-
carcinomas, 75% of non-small cell lung (NSCLC) cancers,
and 26% of bladder cancers. Although down-regulation of
WIF1 was correlated to higher tumor staging among urinary
bladder tumors, there was no significant correlation
observed with breast, prostate, or non-small cell lung car-
cinomas.319 Later work by Mazieres et al demonstrated CpG
island hypermethylation in the WIF-1 promoter of human
lung cancer cell lines and in 15 of 18 (83%) resected NSCLC
tumors. Treatment of cell lines with the DNA methyl-
transferase inhibitor 5-aza-20-deoxycytidine restored WIF-1
expression.320
Epigenetic inactivation of WIF-1 expression has since
been shown to be a common mechanism for WIF-1 down-
regulation across multiple tumor types. Hypermethylation
of the WIF1 promoter was correlated to loss of WIF-1
expression by Batra et al in four out of four malignant
pleural mesothelioma cell lines, and seven of eight primary
tissue samples.321 Demonstration of similar results in cell
lines and primary tumor samples of osteosarcoma, breast
adenocarcinoma, nasopharyngeal carcinoma, esophageal
carcinoma, and urinary tract transitional-cell carcinomasuggests that WIF-1 promoter hypermethylation may be a
common mechanism for Wnt-mediated tumorigenesis and a
potential therapeutic target for multiple cancers.45,322e325
To this end, experimentation by Hoang and colleagues has
demonstrated that overexpression of WIF-1 in the highly
metastatic osteosarcoma cell line, 143B, led to statistically
significant inhibition of primary tumor growth and
decreased the frequency of pulmonary metastases in a
murine xenograft model.326 This work lends promise to the
therapeutic benefits of targeting Wnt signaling in a broad
range of tumor types. However, it specifically is a step in
the right direction towards development of novel therapies
for osteosarcoma, a disease characterized by inter-tumor
variability in its molecular signature and clinical outcomes
which have remained largely stagnant despite optimization
of conventional surgical and cytotoxic treatments.327e330
Epigenetic silencing of DKKs is found in some human
cancers
Downregulation of DKK-1, indicating loss of the Dkk-1-
mediated negative feedback loop regulating canonical
Wnt signaling, has been reported in colon adenocarci-
nomas.186 This downregulation was found to be a result of
CpG island promoter hypermethylation in the DKK-1 pro-
moter. Promoter hypermethylation was found in nine of 54
(17%) of primary colorectal tumors analyzed and, relative
to promoters SFRP-1 and WIF-1, selectively hyper-
methylated in advanced neoplasms, defined as Dukes’ C
and D tumors.331 In their analysis of colon cancer lines and
primary tumor samples, Yu et al report a higher incidence
of promoter hypermethylation for DKK-3. They observed
hypermethylation in 3 of 9 cell lines (33.3%) and 67 of 128
primary tumors (52.3%). Although DKK-3 silencing was
correlated to poor outcomes with gastric cancer (see
below), no correlation was observed with colorectal
cancer.332
Nozaki et al report similar results among NSCLC. In their
analysis of 57 surgically-resected tumors, 36 (63%) had
reduced expression of Dkk-3. Downregulation was
frequently observed in poorly-differentiated adenocarci-
nomas and squamous cell carcinoma. The authors propose
that reduced expression of DKK-3 may explain rapid cell
proliferation in NSCLCs.333
In studies of gastric cancer, epigenetic silencing of DKK-3
has been found to be a common event and one of prognostic
significance. Yu et al reported promoter hypermethylation
of DKK-3 in 12 of 17 gastric cancer cell lines (70.6%) and in
117 of 173 (67.6%) primary gastric tumors. Multivariate
analysis revealed that DKK-3 methylation was significantly
associated with poor disease survival (relative risk, 2.534).
KaplaneMeier survival curves demonstrated that gastric
cancer patients with DKK-3 methylation had significantly
shorter survival (median of 0.76 years) than their counter-
parts without DKK-3 methylation (median of 2.68 years).332
Wnt ligand-dependent pathways for tumorigenesis
remain uncommon and are not fully understood
While ligand-independent pathways, primarily secondary to
mutations in APC or CTNNB1, remain the most commonly
described link between canonical Wnt signaling and
tumorigenesis, there are reports of tumors with over-
expression of Wnt ligands.
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reported in human breast cancer cell lines. Since the dis-
covery of Wnt1/Int1 as a virally-induced oncogene for
MMTV, the role of Wnt in breast carcinogenesis has been a
topic of study. Abnormal expression of b-catenin and cyclin
D1 has been found frequently among breast cancer cell
lines and patient samples.334 Although increased expression
of cyclin D1 has previously been reported in approximately
half of all breast cancers, gene amplification accounts for
less than 20% of cases.335,336 In an analysis of 123 patient
samples, Lin et al found expression of b-catenin and cyclin
D1 to be associated with significantly poorer patient prog-
nosis and decreased survival.334,337 However, despite the
wealth of evidence suggesting a role for abnormal Wnt
signaling in breast carcinogenesis, genetic abnormalities in
common mutational target genes such as APC and AXIN
have been identified only on rare occasion in malignant
breast tumors.338
In the face of this evidence, Benhaj et al evaluated
expression of several Wnt signaling components, including
the 19 Wnt ligands and 10 known Fz, among six breast
cancer cell lines. They reported an increased, redundant
expression of six canonical Wnt ligands (Wnt3A, Wnt4,
Wnt6, Wnt8B, Wnt9A, Wnt10B) and decreased expression of
WNT5A and WNT5B, which encode non-canonical Wnts,
among breast cancer cell lines. They did not observe dif-
ferential expression of any Fzs between malignant and non-
malignant cell lines. Overexpression of canonical Wnt li-
gands in the malignant cell lines was correlated with nu-
clear accumulation of b-catenin and induction of CCND1
expression.338 These results suggest that ligand-dependent
induction of Wnt signaling may play a significant role in the
development of breast cancer and presents a new class of
potential therapeutic targets in the treatment of this dis-
ease. Epigenetic silencing of Wnt antagonists in breast
cancer has since been reported (reviewed above), and
likely works in concert with direct activation of canonical
Wnt signaling.Dysregulation of Wnt signaling is implicated in
cancer drug resistance
In addition its clear role in carcinogenesis, a growing body
of evidence suggests that unregulated activation of b-cat-
enin may play a significant role in the development of
resistance to traditional cytotoxic chemotherapy. Perhaps
more importantly, several of these studies demonstrate
reversal of resistance following inhibition or silencing of
canonical Wnt signaling.
Wnt/b-catenin-mediated chemoresistance is
characterized by increased Wnt pathway activity in
tumors and is reversible with inhibition of Wnt
signaling
Chemoresistance of HCC to cisplatin, used extensively in
the treatment of unresectable cases, presents challenges
to treatment of HCC and remains poorly understood.
Abnormal activation of the canonical pathway, known to
play a role in the development of HCC (see prior sections),has been proposed as a likely mechanism for this resis-
tance. Studies supporting b-catenin-mediated resistance to
cisplatin in HCC include work on adult hepatic progenitor
(oval) cells.339 Increased proliferation of oval cells, known
to give rise to HCC, was initially observed following forced
expression of a constitutively-active b-catenin
mutant.339,340 Activation of Wnt signaling led to enrichment
of HCC OV6þ cells, a progenitor-like subpopulation with
known chemoresistance, in HCC cell lines and tumor sam-
ples. Resistance of OV6 cells to cisplatin was reversible with
lentiviral microRNA (miRNA)-mediated knockdown of
CTNNB1. In addition to identifying a specific subpopulation
of cells responsible for the chemoresistance of HCC, this
work highlights the potential of canonical Wnt signaling as a
druggable target for reversing this resistance.339
These results have since been added to by the work of
Wei et al, who modified Huh7 cells to exhibit cisplatin-
resistance and found that they demonstrated nuclear
accumulation of b-catenin, a sign of abnormal canonical
signaling. Sorafenib, a kinase inhibitor drug known to
improve median survival in unresectable or advanced HCC,
was shown to sensitize these cisplatin-resistant Huh7 cells
to cisplatin both in vitro and in vivo. These effects were
abrogated by addition of the canonical ligand Wnt3a.341
Although not used as extensively as cisplatin, combina-
tion therapy with interferon a and the cytotoxic pyrimidine
analog 5-fluorouracil (5-FU) is used to good effect in the
treatment of HCC tumors with expression of Type I inter-
feron receptor type 2 (IFNAR2). In IFNAR2þ patients with
poor response to therapy, chemoresistance has been shown
to be associated with increased canonical Wnt signaling by
Noda et al, suggesting that this pathway may be implicated
broadly in chemoresistance of HCC.342
b-Catenin-mediated chemoresistance to the cytotoxic
drug doxorubicin has been reported in neuroblastoma, a
primarily pediatric cancer and the most common extra-
cranial tumor occurring in childhood. Cells from the neu-
roblastoma cell line SK-N-SH expressing CD133, a known
CSC marker, are known to be more resistant to cytotoxic
therapies such as doxorubicin than their CD133 counter-
parts.343,344 Work published by Vangipuram et al in 2012
implicates canonical Wnt signaling in this resistance.
Overall, Wnt pathway activity was higher in CD133þ cells
than in CD133, both with and without doxorubicin. In
response to treatment with doxorubicin (100 ng/mL over
48 hours), overall Wnt activity was suppressed in CD133
SK-N-SH cells as shown by Wnt PCR Array. By comparison,
Wnt activity was upregulated in doxorubicin-treated
CD133þ cells. As expected, a higher percentage of
CD133þ cells survived doxorubicin treatment. Combined
treatment with doxorubicin and one of the Wnt pathway
inhibitors XAV-939 and ICG-001 led to statistically similar
rates of cell death in both groups. When treated with only
ICG-001, CD133 had a significantly higher percentage of
cell survival.345
Chemoresistance is the perhaps the greatest challenge
in treatment of OS, a disease whose standard therapy in-
cludes multi-drug regimens which, despite optimization,
have failed to produce improvements in overall survival for
the past three decades.329,330,346 In their study of the
human OS cell line SaOS2, Ma et al demonstrated upregu-
lation of the Wnt signaling components Wnt3a, b-catenin,
Wnt signaling in stem cell biology and tumorigenesis 29and Lef1 in SaOS2 relative to human fetal osteoblasts.
Sensitivity to the cytotoxic drug methotrexate, which in
combination with adriamycin and doxorubicin is the most
commonly-used multi-drug regimen in the treatment of OS,
was enhanced by knockdown of b-catenin. Sensitivity
increased further when both inhibitors of b-catenin and the
Notch signaling pathway were used, suggesting that multi-
ple pathways may be responsible for the extensive drug
resistance seen in OS.347Increased Wnt pathway activity underlying cancer
drug resistance occurs due to dysregulation at
multiple levels
As with tumorigenesis, current evidence suggests multiple
mechanisms by which abnormal Wnt signaling contributes
to chemoresistance in cancer.
Increased signaling due to upregulation of Wnt ligands,
specifically Wnt5a, has been shown to contribute to poor
clinical outcomes and increased drug resistance in ovarian
carcinoma. Peng et al reported that expression of Wnt5a
was higher in malignant ovarian tumors than in benign or
normal tissue and that increasing expression was correlated
with a decrease in both overall and disease-free survival.
Overexpression of Wnt5a in ovarian carcinoma cell lines
decreased chemosensitivity, while miRNA-mediated
silencing of WNT5A led to a significant increase in
chemosensitivity.348
Increased expression of Fz as a cause of chemo-
resistance has been reported in studies of neuroblastoma.
Comparison of gene expression between two parental
neuroblastoma cell lines and their doxorubicin-resistant
derivate cell lines revealed FZD1 as the most differentially
expressed gene. Silencing of FZD1 restored the
doxorubicin-sensitive phenotype and, interestingly, par-
allel down-regulation of MDR1, a b-catenin target gene
encoding a multi-drug transporter and a known mediator
of chemoresistance. Upregulation of FZD1 and/or MDR1
were found in post-treatment tumor samples as well. Of
note, b-catenin target genes encoding cell cycle regulators
such as Cyclin-D1 and IGF-2 were differentially upregu-
lated as well in the doxorubicin-resistant cell lines. Taken
together, these results suggest that FZD1-mediated che-
moresistance is likely due to upregulation of MDR1, as well
an array of proliferative and cell survival
characteristics.349
Emerging evidence suggests that changes in levels of
miRNAs, potent regulators of gene expression, may play a
large role in tumorigenesis and may be responsible for
several examples of cancer drug resistance.350(p1),351 In the
case of HCC, Xu et al discovered increased levels of miR-
130a in HCC patients following treatment with cisplatin-
based chemotherapy. They demonstrated a decrease in
cisplatin-induced inhibition of proliferation in Huh7 cells
with forced expression of miR-130a, and increased inhibi-
tion following knockdown of miR-130a. Huh7 cells resistant
to cisplatin (Huh7-R) exhibited nuclear accumulation of b-
catenin, while Huh7 cells did not. Further studies aimed at
elucidating the mechanism for these observations revealed
runt-related transcription factor 3 (RUNX3) as a target of
miR-130a. Inhibition of RUNX3 by siRNA led to an increase inWnt signaling. Taken together, these results confirm that
inhibition of RUNX3 by increasing levels of miR-130a upre-
gulates Wnt signaling and contributes to cisplatin resistance
in HCC.352
Conclusions and future directions
The evolutionarily conserved Wnt signaling pathway plays
an indispensable role in regulating a diverse range of
cellular activities. The past 10 years have seen a rapid
expansion in our understanding of the regulatory circuitry
and the complexity of this pathway as new components of
Wnt signaling, especially those related to signaling regula-
tion, stem cell renewal, and tissue homeostasis, have been
identified and characterized.
However, the exact mechanisms underlying Wnt
signaling under physiological and pathological conditions
remain far from fully understood. Many critical questions
remain to be fully explored, including the specificity of the
interaction between Wnt ligands, Fz receptors and co-
receptors, the level of signaling at which canonical or non-
canonical Wnt signaling is determined, and further study of
upstream regulatory signals of Wnt signaling. The rela-
tionship of individual Wnt ligands with downstream target
genes in varying tissue or cell types and the nature of their
interaction with secreted antagonists remain to be fully
explored as well. It is also critical to understand how
extensively Wnt signaling cross-talks with other major
signaling pathways. With rapid technological advances in
genomics and systems biology, however, we remain hopeful
that satisfactory answers to these questions will continue
to be pursued and may be discovered as soon as in the next
decade.
Accompanying these advances in our understanding of
Wnt signaling regulation and complexity is an increasing
awareness of its role not only in physiological development,
but in the development of human pathology, especially
cancers, when regulatory aspects of the pathway go awry.
While allowing us to unravel the pathophysiology of several
cancers, many of which have heretofore proven challenging
to cure, these new discoveries present a new class of po-
tential therapeutic targets in the management of malignant
and non-malignant Wnt-associated diseases.
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